Scarborough Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Scarborough Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27	Closed	-$1.52K	–	211
2026 Q1	$1.52K	Hold	27	–	–	﹤0.01%	614
2025 Q4	$1.6K	Hold	27	–	–	﹤0.01%	375
2025 Q3	$1.46K	Hold	27	–	–	﹤0.01%	369
2025 Q2	$1.48K	Buy	+27	New	+$1.59K	﹤0.01%	360
2024 Q3	–	Sell	-27	Closed	-$2.22K	–	165
2024 Q2	$2.22K	Hold	27	–	–	﹤0.01%	301
2024 Q1	$2.36K	Hold	27	–	–	﹤0.01%	297
2023 Q4	$2.6K	Buy	+27	New	+$2.39K	﹤0.01%	546

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Scarborough Advisors's BMRN Position: Q2 2026 in Review

Scarborough Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 27 shares — an estimated $1.52K sold.

Scarborough Advisors first reported a position in BMRN in Q4 2023 and held it in 7 quarters. The position peaked at $2.6K in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Scarborough Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Scarborough Advisors sold 27 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.52K.
Scarborough Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Scarborough Advisors's BioMarin Pharmaceuticals position peaked at $2.6K in Q4 2023.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.